Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Next Previous
Trial Profile

A Phase 1 Study of BLU-285 in Patients With Advanced Systemic Mastocytosis (AdvSM) and Relapsed or Refractory Myeloid Malignancies

Status: Completed
Phase of Trial: Phase I

Latest Information Update: 17 Jun 2025

Price :
$35 *
Note:
  • Adis is an information provider.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
  • A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

  • Drugs Avapritinib (Primary)
  • Indications Chronic myelomonocytic leukaemia; Haematological malignancies; Leukaemia; Mast Cell Leukemia; Mastocytosis; Myeloid leukaemia; Systemic mastocytosis
  • Focus Adverse reactions; Proof of concept; Registrational
  • Acronyms EXPLORER
  • Sponsors Blueprint Medicines

Most Recent Events

  • 12 Jun 2025 According to a Blueprint Medicines media release, data from the trial will be reported at the 2025 European Hematology Association (EHA2025) Hybrid Congress, being held June 12 to 15 in Milan, Italy, and the European Academy of Allergy and Clinical Immunology (EAACI) Congress 2025, being held June 13 to 16 in Glasgow, United Kingdom.
  • 12 Jan 2023 Status changed from active, no longer recruiting to completed.
  • 13 Dec 2022 Results assessing long-term safety and efficacy presented at the 64th American Society of Hematology Annual Meeting and Exposition.

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top